• Organoid  SB202190
  • Organoid  A-83-01
  • Human Liver Ductal Organoid Kit (Differentiation)
  • Human Liver Ductal Organoid Kit (Differentiation)
  • Organoid  SB202190
  • Organoid  A-83-01
  • Human Liver Ductal Organoid Kit (Differentiation)
  • Human Liver Ductal Organoid Kit (Differentiation)

Organoid SB202190

SB202190 is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 binds to the ATP pocket of the active recombinant human p38 kinase with a Kd of 38 nM. SB 202190 has anti-cancer activity and rescued memory deficits. SB202190 induces autophagy.
  • Organoid  SB202190
  • Organoid  A-83-01
  • Human Liver Ductal Organoid Kit (Differentiation)
  • Human Liver Ductal Organoid Kit (Differentiation)

SPECIFICATION

Organoids refer to tissue analogues with a certain spatial structure formed by three-dimensional cultivation of adult stem cells or pluripotent stem cells in vitro. Organs are highly consistent with their source tissues in terms of tissue structure, cell type, self-renewal ability, and function, thus demonstrating unique advantages in multiple biomedical fields such as developmental biology, disease modeling, precision medicine, drug research and development, gene and cell therapy, infection and immunity, and regenerative medicine.

Product Description:

SB202190 is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 binds to the ATP pocket of the active recombinant human p38 kinase with a Kd of 38 nM. SB 202190 has anti-cancer activity and rescued memory deficits. SB202190 induces autophagy.

BIOLOGICAL ALTIVITY
In Vitro
SB202190 (0-10 μM; 0-72 hours) attenuates growth of a subgroup of CRC cell lines such as RKO, CACO2 and SW480 in a dose- and time-dependent manner.
SB 202190 strongly inhibited colony formation and anchorage-independent growth (10 μM for 7–10 days) and elevated apoptotic cell death (10 μM for 72 h) in this same subset of CRC lines (RKO, CACO2 and SW480).
In RKO, CACO2 and SW480 cells, SB202190 (10 μM; 2 hours) abrogates phosphorylation of S6K1(T389) and S6(S235/236), but not AKT(S473), indicating that p38i selectively blocks mTORC1 signaling.
In Vivo
SB202190 (5 mg/kg; intraperitoneal injection; daily for 10-12 days) shows inhibition of tumor cell survival and tumor growth.

CONTACT US
FirstName*
LastName*
Email*
Message*